NCT06965114 2026-04-14Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaNational Cancer Institute (NCI)Phase 1/2 Recruiting84 enrolled
NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts
NCT01326702 2019-12-16Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsNational Cancer Institute (NCI)Phase 1/2 Completed43 enrolled 18 charts
NCT02281279 2016-08-11Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaMayo ClinicPhase 1/2 Withdrawn